A prospective multicentre cohort study investigating the effect of SBRT on oligometastatic colorectal cancer in various locations (liver, lymph nodes, lungs and bone) showed no difference in local control between wild-type and KRAS-mutated cases (p = 0.63). This evidence concerns the gene KRAS and colorectal cancer.